Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients

Transplantation

Volumn 75, Issue 9, 2003, Pages 1429-1436

  Gao, Liquan ^a   Xue, Shao An ^a   Hasserjian, Robert ^b   Cotter, Finbarr ^c   Kaeda, Jaspal ^a   Goldman, John M ^a   Dazzi, Fancesco ^d   Stauss, Hans J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b BAYSTATE MEDICAL CENTER   (United States)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; TRANSCRIPTION FACTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WILM TUMOR ANTIGEN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; LEUKEMIA; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE; STEM CELL TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD34; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MICE; MICE, INBRED NOD; MICE, SCID; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 0037572276     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000061516.57346.E8     Document Type: Article

References (32)

1. Hastie ND. Life, sex, and WT1 isoforms-three amino acids can make all the difference. Cell 2001; 106(4): 391.
2. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001; 273(2): 141.
3. Nakagama H, Heinrich G, Pelletier J, et al. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cell Biol 1995; 15(3): 1489.
4. Herzer U, Crocoll A, Barton D, et al. The Wilms tumor suppressor gene wt1 is required for development of the spleen. Curr Biol 1999; 9(15): 837.
5. Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell 1993; 74(4): 679.
6. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997; 25(4): 312.
7. Ellisen LW, Carlesso N, Cheng T, et al. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. Embo J 2001; 20(8): 1897.
8. Menssen HD, Renkl HJ, Entezami M, et al. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997; 89(9): 3486.
9. Patmasiriwat P, Fraizer G, Kantarjian H, et al. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 1999; 13(6): 891.
10. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999; 13(3): 393.
11. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84(9): 3071.
12. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87(7): 2878.
13. Algar EM, Khromykh T, Smith SI, et al. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 1996; 12(5): 1005.
14. Inoue K, Tamaki H, Ogawa H, et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91(8): 2969.
15. Liu XW, Gong LJ, Guo LY, et al. The Wilms' tumor gene product WT1 mediates the down-regulation of the rat epidermal growth factor receptor by nerve growth factor in PC12 cells. J Biol Chem 2001; 276(7): 5068.
16. Lee SB, Huang K, Palmer R, et al. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 1999; 98(5): 663.
17. Mayo MW, Wang CY, Drouin SS, et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. Embo J 1999; 18(14): 3990.
18. Maheswaran S, Englert C, Bennett P, et al. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 1995; 9(17): 2143.
19. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89(4): 1405.
20. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95(7): 2198.
21. Larochelle A, Vormoor J, Hanenberg H, et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 1996; 2(12): 1329.
22. DeMars R, Chang CC, Shaw S, et al. Homozygous deletion that simultaneously eliminate expression of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol 1984; 11: 77.
23. Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998; 91(7): 2406.
24. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2(2): 123.
25. Dazzi F, Capelli D, Hasserjian R, et al. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood 1998; 92(4): 1390.
26. Bonnet D, Warren EH, Greenberg PD, et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A 1999; 96(15): 8639.
27. de Bueger M, Bakker A, Van Rood JJ, et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149(5): 1788.
28. Warren EH, Gavin M, Greenberg PD, et al. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol 1998; 5(6): 429.
29. Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3(12): 1337.
30. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51(2): 99.
31. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95(1): 286.
32. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2(10): 962.